Compare SURG & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | BDSX |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 122.0M |
| IPO Year | N/A | 2020 |
| Metric | SURG | BDSX |
|---|---|---|
| Price | $0.88 | $19.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.75 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 157.4K | 150.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | $3.78 | $23.35 |
| Revenue Next Year | $113.46 | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.75 | $0.25 |
| 52 Week High | $3.47 | $19.75 |
| Indicator | SURG | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 73.17 |
| Support Level | $0.75 | $6.33 |
| Resistance Level | $0.95 | N/A |
| Average True Range (ATR) | 0.06 | 1.73 |
| MACD | 0.03 | 0.41 |
| Stochastic Oscillator | 64.89 | 89.10 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.